U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
Aug 03, 2026
Read MoreZai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
Jul 22, 2026
Read MoreZai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
Jun 16, 2026
Read MoreZai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Jun 08, 2026
Read MoreZai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
May 11, 2026
Read MoreZai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
May 07, 2026
Read MoreZai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Apr 22, 2026
Read More